Marie Anne Gebara1,2, Elizabeth A DiNapoli2, John Kasckow3, Jordan F Karp2, Daniel M Blumberger4, Eric J Lenze5, Benoit H Mulsant4, Charles F Reynolds2. 1. University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 2. Mental Illness Research, Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA. 3. VA Beckley Healthcare System, Beckley, WV, USA. 4. Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. 5. Washington University School of Medicine, St. Louis, MO, USA.
Abstract
OBJECTIVE: To identify which specific depressive symptoms predict remission to aripiprazole augmentationin late-life treatment resistant depression. METHODS: This is a secondary analysis of data from a late-life treatment resistant depression trial examining the safety and efficacy of aripiprazole augmentation. Participants aged 60 and above were randomized to aripiprazole augmentation (N = 91) versus placebo (N = 90). The main outcome was depression remission. Clinical predictors included individual Montgomery-Asberg Depression Rating Scale (MADRS) item scores categorized as symptomatic (scores >2) or nonsymptomatic (scores ≤2). RESULTS: Three MADRS items predicted depression remission with aripiprazole augmentation: symptomatic scores on sleep disturbance and nonsymptomatic scores on apparent sadness and inability to feel. The 2-way and 3-way interaction terms of these MADRS items were not significant predictors of remission; therefore, the models' ability to predict remission was not improved by combining the significant MADRS items. CONCLUSIONS: The identification of specific depressive symptoms, which can be clinically assessed, can be used to inform treatment decisions. Older adults with treatment resistant depression that present with sleep disturbances, lack of apparent sadness, or lack of inability to feel should be considered for aripiprazole augmentation.
RCT Entities:
OBJECTIVE: To identify which specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression. METHODS: This is a secondary analysis of data from a late-life treatment resistant depression trial examining the safety and efficacy of aripiprazole augmentation. Participants aged 60 and above were randomized to aripiprazole augmentation (N = 91) versus placebo (N = 90). The main outcome was depression remission. Clinical predictors included individual Montgomery-Asberg Depression Rating Scale (MADRS) item scores categorized as symptomatic (scores >2) or nonsymptomatic (scores ≤2). RESULTS: Three MADRS items predicted depression remission with aripiprazole augmentation: symptomatic scores on sleep disturbance and nonsymptomatic scores on apparent sadness and inability to feel. The 2-way and 3-way interaction terms of these MADRS items were not significant predictors of remission; therefore, the models' ability to predict remission was not improved by combining the significant MADRS items. CONCLUSIONS: The identification of specific depressive symptoms, which can be clinically assessed, can be used to inform treatment decisions. Older adults with treatment resistant depression that present with sleep disturbances, lack of apparent sadness, or lack of inability to feel should be considered for aripiprazole augmentation.
Authors: Eric J Lenze; Benoit H Mulsant; Daniel M Blumberger; Jordan F Karp; John W Newcomer; Stewart J Anderson; Mary Amanda Dew; Meryl A Butters; Jacqueline A Stack; Amy E Begley; Charles F Reynolds Journal: Lancet Date: 2015-09-27 Impact factor: 79.321
Authors: Stephen F Smagula; Meredith L Wallace; Stewart J Anderson; Jordan F Karp; Eric J Lenze; Benoit H Mulsant; Meryl A Butters; Daniel M Blumberger; Breno S Diniz; Francis E Lotrich; Mary Amanda Dew; Charles F Reynolds Journal: J Psychiatr Res Date: 2016-07-07 Impact factor: 4.791
Authors: D J Buysse; C F Reynolds; C C Hoch; P R Houck; D J Kupfer; S Mazumdar; E Frank Journal: Neuropsychopharmacology Date: 1996-04 Impact factor: 7.853
Authors: Shriya H Kaneriya; Gregg A Robbins-Welty; Stephen F Smagula; Jordan F Karp; Meryl A Butters; Eric J Lenze; Benoit H Mulsant; Daniel Blumberger; Stewart J Anderson; Mary Amanda Dew; Francis Lotrich; Howard J Aizenstein; Breno S Diniz; Charles F Reynolds Journal: JAMA Psychiatry Date: 2016-04 Impact factor: 21.596
Authors: Christopher M Callahan; Kurt Kroenke; Steven R Counsell; Hugh C Hendrie; Anthony J Perkins; Wayne Katon; Polly Hitchcock Noel; Linda Harpole; Enid M Hunkeler; Jürgen Unützer Journal: J Am Geriatr Soc Date: 2005-03 Impact factor: 5.562
Authors: Eric J Lenze; Meera Sheffrin; Henry C Driscoll; Benoit H Mulsant; Bruce G Pollock; Mary Amanda Dew; Frank Lotrich; Bernie Devlin; Robert Bies; Charles F Reynolds Journal: Dialogues Clin Neurosci Date: 2008 Impact factor: 5.986
Authors: Helene M Altmann; Joseph Kazan; Marie Anne Gebara; Daniel M Blumberger; Jordan F Karp; Eric J Lenze; Benoit H Mulsant; Charles F Reynolds; Sarah T Stahl Journal: Am J Geriatr Psychiatry Date: 2022-03-10 Impact factor: 7.996